Last updated: 2026-09-08 22:22:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Senseonics Holdings, Inc. (SENS) operates in the INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL sector and is listed on NASDAQ. The stock is currently priced at $9.30, with a market capitalization of $509.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.79 to $11.58. This page covers its latest market performance, valuation, price trends and company information.
$509.18M | |
$9.61 | |
$111.20 | |
$4.79 | |
$9.63 | |
477.66K | |
742.12K | |
-- | |
$11.58 | |
$4.79 | |
-- | |
-- |
Senseonics Holdings, Inc. (SENS) is trading at $9.31 in after-hours trading as of 2026-09-08 22:07:00, down 3.32% ($0.32) from the regular-session close of $9.63.
After-hours trading shows how investors are pricing SENS after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Senseonics Holdings, Inc. (SENS) moved from $9.40 to $9.30, representing a decline of 1.04% ($0.10).
The stock traded between $9.09 and $10.15 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 561.80 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66.5%
SENS is currently trading at $9.30, placing it 66.5% of the way from its 52-week low of $4.79 to its 52-week high of $11.58. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
| Industry | INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Senseonics Holdings, Inc. (SENS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.